274 related articles for article (PubMed ID: 18030307)
1. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients.
Michaud V; Vanier MC; Brouillette D; Roy D; Verret L; Noel N; Taillon I; O'Hara G; Gossard D; Champagne M; Goodman K; Renaud Y; Brown A; Phillips M; Ajami AM; Turgeon J
Clin Pharmacol Ther; 2008 May; 83(5):740-8. PubMed ID: 18030307
[TBL] [Abstract][Full Text] [Related]
2. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
3. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
[TBL] [Abstract][Full Text] [Related]
4. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
[TBL] [Abstract][Full Text] [Related]
5. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
[TBL] [Abstract][Full Text] [Related]
6. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
7. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
[TBL] [Abstract][Full Text] [Related]
8. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG
Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
[TBL] [Abstract][Full Text] [Related]
10. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
[TBL] [Abstract][Full Text] [Related]
11. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
[TBL] [Abstract][Full Text] [Related]
12. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
13. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.
Ferder NS; Eby CS; Deych E; Harris JK; Ridker PM; Milligan PE; Goldhaber SZ; King CR; Giri T; McLeod HL; Glynn RJ; Gage BF
J Thromb Haemost; 2010 Jan; 8(1):95-100. PubMed ID: 19874474
[TBL] [Abstract][Full Text] [Related]
14. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
[TBL] [Abstract][Full Text] [Related]
16. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
17. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
[TBL] [Abstract][Full Text] [Related]
18. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
Aomori T; Obayashi K; Fujita Y; Araki T; Nakamura K; Nakamura T; Kurabayashi M; Yamamoto K
Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
